NCT01353508View on ClinicalTrials.gov

Sodium Excretion of LCZ696 in Patients With Hypertension; Heart Failure and Healthy Volunteers

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Hypertension
Interventions
DRUG

LCZ696

200 mg and 400 mg tablets

DRUG

Valsartan

160 mg tablets

Trial Locations (1)

117198

Novartis Investigative Site, Moscow

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY